Spontaneous evolution of essential thrombocythaemia into acute megakaryoblastic leukaemia with trisomy 8, trisomy 21 and cutaneous involvement

European Journal of Haematology

Volumn 71, Issue 6, 2003, Pages 466-469

  Paolini, Rossella ^a   Bonaldi, Laura ^b   Bianchini, Enzo ^a   Ramazzina, Emilio ^a   Cella, Giuseppe ^b  

^a ROVIGO GENERAL HOSPITAL   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Acute megakaryoblastic leukaemia; Essential thrombocythaemia; Trisomy 8

Indexed keywords

ACETYLSALICYLIC ACID; CYTARABINE; IDARUBICIN; WARFARIN;

ACUTE MEGAKARYOCYTIC LEUKEMIA; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL FEATURE; CYTOGENETICS; DEATH; DEEP VEIN THROMBOSIS; DISEASE ACTIVITY; DISEASE COURSE; FOLLOW UP; HEPATOSPLENOMEGALY; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; LABORATORY TEST; MALE; MEGAKARYOBLAST; MEGAKARYOCYTE; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SKIN DISEASE; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TRISOMY 21; TRISOMY 8;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW; CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; FATAL OUTCOME; HEPATOMEGALY; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, MEGAKARYOCYTIC, ACUTE; MALE; MEGAKARYOCYTES; MIDDLE AGED; SKIN; SPLENOMEGALY; THROMBOCYTHEMIA, HEMORRHAGIC; TRISOMY;

EID: 0345393112     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0902-4441.2003.00139.x     Document Type: Article

References (22)

1. TEFFERI A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leuk Res 2001;25:369-377.
2. FINAZZI G, RUGGERI M, RODEGHIERO F, BARBUI T. Second malignancies in patients with essential thrombocythemia treated with busulfan and hydroxyurea: long-term follow-up of randomized clinical trial. Br J Haematol 2000;110:577-583.
3. ROZMAN C, GIRALT M, FELIU E, RUBIO D, CORTES MT. Life expectancy of patients with chronic nonleukemic myeloproliferative disorders. Cancer 1991;67:2658-2663.
4. MICHIELS JJ. Normal life expectancy and thrombosis-free survival in aspirin treated essential thrombocythemia. Clin Appl Thromb Hemost 1999;5:30-36.
5. PASSAMONTI F, MALABARBA L, ORLANDI E et al. Pipobroman is safe and effective treatment for patients with essential thrombocythemia at high risk of thrombosis. Br J Haematol 2002;116:855-861.
6. STERKERS Y, PREUDHOMME C, LAÏ JL, DEMORY JL, CAULIER MT, WATTEL E, BORDESSOULE D, BAUTERS F, FENAUX P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622.
7. RANDI ML, FABRIS F, GIROLAMI A. Second malignancies in patients with essential thrombocythemia. Br J Haematol 2002;116:923-924.
8. HARRISON CN. Current trends in essential thrombocythemia. Br J Haematol 2002;117:796-808.
9. GELLER SA, SHAPIRO E. Acute leukemia as a natural sequel to primary thrombocythemia. Am J Clin Pathol 1982;77:353-356.
10. ANDERSOON PO, RIDELL B, WADENVIK H, KUTTI J. Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment. Ann Hematol 2000;79:40-42.
11. HATTORI A, NAGAYAMA R, KISHI K, FUSE I, HANANO M, TAKIZAWA S. TAKESHIGE T, SHIBATA A. Primary thrombocythemia in Japan: a survey of 225 patients. Leuk Lymphoma 1991;4:177-186.
12. RADAELLI F, MAZZA R, CURIONI E, CIANI A, POMATI M, MAIOLO A-T. Acute megakaryocytic leukaemia in essential thrombocythemia: an unusual evolution? Eur J Haematol 2002;69:108-111.
13. LIOZON E, BRIGAUDEAU C, TRIMOREAU F, DESANGLES F, FERMEAUX V, PRALORAN V, BORDESSOULE D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukemic transformation and review of the literature. Hematol Cell Ther 1997;39:11-18.
14. BERNASCONI P, BONI M, CAVIGLIANO PM et al. Acute myeloid leucemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea. Leukemia 2002;16:2078-2083.
15. UOZUMI K, OHNO N, SHIMOTAKAHARA S, SUZUKI S, TAKEUCHI S, HANADA S, ARIMA T. Trisomy 8 in essential thrombocythemia in leukemic transformation. Cancer Genet Cytogenet 2000;116:84-86.
16. HYROSE Y, MASAKI Y, SUGAI S. Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases. Eur J Haematol 2002;68:112-116.
17. MURPHY S, PETERSON P, ILAND H, LASZLO J. Experience of Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. Semin in Hematol 1997;34:29-39.
18. ANDERSEN MK, PEDERSEN-BJERGAARD J, KJELDSEN L, DUFVA IH, BRØNDUM-NIELSEN K. Clonal Ph-negative hematopoiesis in CML after therapy with imatinib mesylate is frequently characterized by trisomy 8. Leukemia 2002;16:1390-1395.
19. HEIM S, MITELMAN F. Cancer Cytogenet, 2nd edn. New York: Wiley-Liss, Inc., 1995:69-140.
20. MILLER KB. Clinical manifestations of acute myeloid leukaemia. In: HOFFMAN R, BENZ EJ, SHATTIL SJ, FURIE B, COHEN HJ, SILBERSTAI LE, eds. Haematology: Basic Principles and Practice, 2nd edn. New York: Churchill Livingstone, 1995:993-1014.
21. AGIS H, WELTERMANN A, FONATSCH C et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. Ann Hematol 2002;81:90-95.
22. MACFARLANE AW, PARRY DH, CASLIN AW, HUGHES M. Cutaneous lesions in a case of acute megakaryoblastic leukaemia. Clin Exp Dermatol 1996;21:201-204.